Pharmaron Beijing Co., Ltd. (HKG:3759)
24.16
+0.52 (2.20%)
Sep 10, 2025, 1:45 PM HKT
Pharmaron Beijing Revenue
Pharmaron Beijing had revenue of 3.34B CNY in the quarter ending June 30, 2025, with 13.92% growth. This brings the company's revenue in the last twelve months to 13.11B, up 14.00% year-over-year. In the year 2024, Pharmaron Beijing had annual revenue of 12.28B with 6.39% growth.
Revenue (ttm)
13.11B CNY
Revenue Growth
+14.00%
P/S Ratio
4.06
Revenue / Employee
613.58K CNY
Employees
21,370
Market Cap
58.30B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 12.28B | 737.78M | 6.39% |
Dec 31, 2023 | 11.54B | 1.27B | 12.39% |
Jan 1, 2023 | 10.27B | 2.82B | 37.92% |
Dec 31, 2021 | 7.44B | 2.31B | 45.00% |
Dec 31, 2020 | 5.13B | 1.38B | 36.64% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
Hansoh Pharmaceutical Group Company | 14.45B |
JD Health International | 71.34B |
Innovent Biologics | 12.52B |
Sino Biopharmaceutical | 33.49B |
WuXi Biologics | 21.98B |
Akeso | 2.75B |
CSPC Pharmaceutical Group | 28.49B |